Chimeric antigen receptor (CAR)-T cell exhaustion limits durable therapeutic efficacy, particularly under persistent antigen stimulation. While transcriptomic and epigenomic analyses have advanced the understanding of CAR-T cell exhaustion, the contribution of microRNAs (miRNAs) remains poorly characterized. Here, we p...
Noriko Nakamura, Hyemin Seo, Risa Hamada et al.· Biochemical and Biophysical...· 0 citations
Bispecific antibodies (BsAbs) are emerging immunotherapeutics that simultaneously engage two distinct targets. This property provides unique mechanisms of action that are not achieved by conventional monoclonal antibodies, including cell-cell bridging, modulation of multiple signaling pathways, and recruitment of diver...
Toshiya Hino, Yusuke Ito, Yuki Kagoya· International Immunology· 0 citations
A CAR T-cell approach targeting an intracellular oncoprotein WT1 presented across diverse HLA-II families is developed, establishing a framework for CAR therapies against intracellular antigens, extending potential CAR T-cell applications to new cancer types and patient populations.
Evey Y F Zheng, Chung-Hsi Wang, T. Ochi et al.· Blood Cancer Discovery· 0 citations
How genetic modulation of NK-cell differentiation pathways may contribute to the establishment of next-generation CAR-NK cell therapies with improved durability and antitumor efficacy is discussed.
Takahiro Nakashima, Yuki Kagoya· [Rinsho ketsueki] The Japane...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
